GT Biopharma Appoints New Member to its Board of Directors
GT Biopharma (NASDAQ: GTBP), a clinical stage immuno-oncology company, has announced the appointment of Andrew Ritter to its Board of Directors, replacing Dr. Rajesh Shrotriya. Ritter brings over 20 years of leadership experience in biotechnology and healthcare technology to GTBP's board.
Currently serving as CEO of Cairns Health, Ritter's track record includes successful leadership roles at Docbot and Ritter Pharmaceuticals. At Ritter Pharmaceuticals, which he founded and led for nearly 17 years, he guided the company through clinical trials and achieved a NASDAQ listing. He holds a B.A. from USC and an MBA from Wharton.
GT Biopharma (NASDAQ: GTBP), un'azienda di immuno-oncologia in fase clinica, ha annunciato la nomina di Andrew Ritter nel suo Consiglio di Amministrazione, in sostituzione del Dr. Rajesh Shrotriya. Ritter porta con sé oltre 20 anni di esperienza dirigenziale nei settori della biotecnologia e della tecnologia sanitaria.
Attualmente CEO di Cairns Health, Ritter vanta una carriera di successo in ruoli di leadership presso Docbot e Ritter Pharmaceuticals. Quest'ultima, da lui fondata e guidata per quasi 17 anni, è stata condotta attraverso studi clinici fino alla quotazione al NASDAQ. Ha conseguito una laurea in lettere presso la USC e un MBA alla Wharton.
GT Biopharma (NASDAQ: GTBP), una empresa de inmuno-oncología en etapa clínica, ha anunciado el nombramiento de Andrew Ritter en su Junta Directiva, reemplazando al Dr. Rajesh Shrotriya. Ritter aporta más de 20 años de experiencia en liderazgo en biotecnología y tecnología sanitaria a la junta de GTBP.
Actualmente es CEO de Cairns Health, y su trayectoria incluye roles exitosos de liderazgo en Docbot y Ritter Pharmaceuticals. En Ritter Pharmaceuticals, que fundó y dirigió durante casi 17 años, lideró la empresa a través de ensayos clínicos y logró la cotización en NASDAQ. Posee una licenciatura de USC y un MBA de Wharton.
GT Biopharma (NASDAQ: GTBP)는 임상 단계 면역종양학 회사로, Andrew Ritter를 이사회에 임명했으며 Dr. Rajesh Shrotriya를 대체합니다. Ritter는 생명공학 및 의료 기술 분야에서 20년 이상의 리더십 경험을 GTBP 이사회에 제공합니다.
현재 Cairns Health의 CEO인 Ritter는 Docbot과 Ritter Pharmaceuticals에서 성공적인 리더십 경력을 쌓았습니다. 거의 17년 동안 설립하고 이끈 Ritter Pharmaceuticals에서는 임상 시험을 진행하고 NASDAQ 상장을 달성했습니다. USC에서 학사 학위를, Wharton에서 MBA를 취득했습니다.
GT Biopharma (NASDAQ : GTBP), une société d'immuno-oncologie en phase clinique, a annoncé la nomination de Andrew Ritter au sein de son conseil d'administration, en remplacement du Dr Rajesh Shrotriya. Ritter apporte plus de 20 ans d'expérience en leadership dans les domaines de la biotechnologie et des technologies de la santé au conseil de GTBP.
Actuellement PDG de Cairns Health, Ritter possède un parcours réussi à des postes de direction chez Docbot et Ritter Pharmaceuticals. Chez Ritter Pharmaceuticals, qu'il a fondée et dirigée pendant près de 17 ans, il a piloté l'entreprise à travers des essais cliniques et obtenu une cotation au NASDAQ. Il est titulaire d'un B.A. de l'USC et d'un MBA de Wharton.
GT Biopharma (NASDAQ: GTBP), ein klinisch tätiges Immunonkologie-Unternehmen, hat die Ernennung von Andrew Ritter in seinen Vorstand bekannt gegeben, der Dr. Rajesh Shrotriya ersetzt. Ritter bringt über 20 Jahre Führungserfahrung in den Bereichen Biotechnologie und Gesundheitstechnologie in den GTBP-Vorstand ein.
Derzeit CEO von Cairns Health, kann Ritter auf erfolgreiche Führungspositionen bei Docbot und Ritter Pharmaceuticals zurückblicken. Bei Ritter Pharmaceuticals, das er gründete und fast 17 Jahre leitete, führte er das Unternehmen durch klinische Studien und erreichte eine Notierung an der NASDAQ. Er besitzt einen B.A. von der USC und einen MBA von Wharton.
- Appointment of experienced biotech executive with proven track record of successful exits
- New board member brings expertise in clinical trials progression and public company leadership
- Addition of director with experience in AI and healthcare technology integration
- None.
SAN FRANCISCO, CALIFORNIA, May 15, 2025 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary TriKE® natural killer (NK) cell engager platform, today announced the appointment of Andrew Ritter to its Board of Directors. Mr. Ritter will be replacing current board member Dr. Rajesh Shrotriya, who is resigning from his position.
“We are very pleased to welcome Andrew to the Board of Directors. Andrew is a deeply talented biotech executive with a proven track record of building and scaling healthcare companies and leading multiple successful exits,” said Michael Breen, Executive Chairman and Chief Executive Officer of GT Biopharma. “His insight and perspective will be invaluable as our NK engagers advance through clinical trials and GT Biopharma continues to evolve as a company.”
Mr. Ritter has over two decades of leadership experience in biotechnology and healthcare technology. He currently serves as Chief Executive Officer of Cairns Health, an innovator in AI-powered remote care solutions supporting Home and Senior Care. Previously, Mr. Ritter was the Chief Executive Officer of Docbot, an AI-driven MedTech company, for which he successfully led its exit to a strategic. He also founded and served as Chief Executive Officer of Ritter Pharmaceuticals for nearly 17 years, where he guided the company from Phase I through Phase III clinical trials. Under his leadership, Ritter Pharmaceuticals became one of the first microbiome-based biotech companies to go public on NASDAQ and later successfully merged with Qualigen Therapeutics. In addition, he was a founding board member of Myosin Therapeutics, a biotech spin-out from Scripps Research, where he helped secure the company’s initial financing and supported its early growth over a four-year board tenure. Mr. Ritter earned a B.A. in political science at the University of Southern California and a Master of Business Administration at the Wharton School, University of Pennsylvania.
About GT Biopharma, Inc.
GT Biopharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of immuno-oncology therapeutic products based on our proprietary TriKE® NK cell engager platform. Our TriKE® platform is designed to harness and enhance the cancer killing abilities of a patient’s immune system’s natural killer cells. GT Biopharma has an exclusive worldwide license agreement with the University of Minnesota to further develop and commercialize therapies using TriKE® technology. For more information, please visit gtbiopharma.com.
Forward-Looking Statements
Certain statements in this press release may constitute "forward-looking statements" regarding future events and our future results. All statements other than statements of historical facts are statements that could be deemed to be forward-looking statements. These statements are based on current expectations, estimates, forecasts, and projections about the markets in which we operate and the beliefs and assumptions of our management. Words such as "expects," "anticipates," "targets," "goals," "projects", "intends," "plans," "believes," "seeks," "estimates," "endeavors," "strives," "may," or variations of such words, and similar expressions are intended to identify such forward-looking statements. Readers are cautioned that these forward-looking statements are subject to a number of risks, uncertainties and assumptions that are difficult to predict, estimate or verify. Therefore, actual results may differ materially and adversely from those expressed in any forward-looking statements. Such risks and uncertainties include those factors described in our most recent annual report on Form 10-K, as such may be amended or supplemented by subsequent quarterly reports on Form 10-Q, or other reports filed with the Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements. The forward-looking statements are made only as of the date hereof, and we undertake no obligation to publicly release the result of any revisions to these forward-looking statements. For more information, please refer to our filings with the Securities and Exchange Commission.
TriKE® is a registered trademark owned by GT Biopharma, Inc.
Investor Relations Contact:
LifeSci Advisors
Corey Davis, Ph.D.
cdavis@lifesciadvisors.com
212-915-2577
FAQ
Who is Andrew Ritter and why did GTBP appoint him to their board?
What is GT Biopharma's (GTBP) main business focus?
What is Andrew Ritter's previous experience in the biotech industry?
Who did Andrew Ritter replace on GT Biopharma's board of directors?
